China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHA:600062)
China flag China · Delayed Price · Currency is CNY
18.40
+0.05 (0.27%)
Feb 3, 2026, 11:29 AM CST

SHA:600062 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Revenue
10,85411,11911,1779,5229,0348,391
Other Revenue
92.7692.76133.12102.9977.88112.69
10,94711,21211,3109,6259,1128,504
Revenue Growth (YoY)
-4.06%-0.87%17.50%5.64%7.14%-9.35%
Cost of Revenue
4,6524,8324,9044,3074,0483,157
Gross Profit
6,2956,3806,4065,3185,0645,347
Selling, General & Admin
4,0534,1273,9373,4783,5023,764
Research & Development
453.68555.19627.85482.48409.59291.02
Other Operating Expenses
68.3775.98106.24119.35115.75114.41
Operating Expenses
4,5854,7394,6814,0814,0294,173
Operating Income
1,7101,6411,7251,2371,0341,173
Interest Expense
-30.34-15.36-15.4-10.62-11.62-3.66
Interest & Investment Income
185.15198.56190.5689.6881.5551.33
Earnings From Equity Investments
-48.8--16.23--
Currency Exchange Gain (Loss)
9.199.196.618.06-4.97-0.48
Other Non Operating Income (Expenses)
-1-2.3261.36.360.26-10.33
EBT Excluding Unusual Items
1,8241,8311,9681,3571,0991,210
Impairment of Goodwill
-29.41-29.41-28.9--56.68-43.42
Gain (Loss) on Sale of Investments
1.65-1.6413.75.9935.3629.05
Gain (Loss) on Sale of Assets
4446.840.18-2.271.03-22.52
Asset Writedown
-48.86-59.17-57.52-8.43-0.54-0.12
Other Unusual Items
78.8778.8740.8582.7642.6541.92
Pretax Income
1,8701,8671,9371,4351,1211,215
Income Tax Expense
243215.94272.71201.27149.06201.52
Earnings From Continuing Operations
1,6271,6511,6641,234972.131,013
Minority Interest in Earnings
-47-23.026.29-53.59-36.45-8.33
Net Income
1,5801,6281,6701,180935.691,005
Net Income to Common
1,5801,6281,6701,180935.691,005
Net Income Growth
-6.23%-2.55%41.55%26.12%-6.91%-4.74%
Shares Outstanding (Basic)
1,0311,0281,0241,0361,0431,043
Shares Outstanding (Diluted)
1,0321,0281,0241,0361,0431,043
Shares Change (YoY)
0.57%0.33%-1.07%-0.74%-0.00%
EPS (Basic)
1.531.581.631.140.900.96
EPS (Diluted)
1.531.581.631.140.900.96
EPS Growth
-6.77%-2.87%43.09%27.06%-6.91%-4.74%
Free Cash Flow
959.961,1881,245889.57849.251,012
Free Cash Flow Per Share
0.931.161.220.860.810.97
Dividend Per Share
0.4710.4710.2570.5780.4800.290
Dividend Growth
31.93%83.27%-55.54%20.42%65.52%-4.61%
Gross Margin
57.50%56.91%56.64%55.25%55.57%62.87%
Operating Margin
15.62%14.64%15.26%12.85%11.35%13.80%
Profit Margin
14.44%14.52%14.77%12.26%10.27%11.82%
Free Cash Flow Margin
8.77%10.59%11.01%9.24%9.32%11.90%
EBITDA
2,4662,3582,3901,7781,4821,548
EBITDA Margin
22.53%21.03%21.13%18.47%16.26%18.20%
D&A For EBITDA
756.48717.07664.52540.36447.4374.36
EBIT
1,7101,6411,7251,2371,0341,173
EBIT Margin
15.62%14.64%15.26%12.85%11.35%13.80%
Effective Tax Rate
12.99%11.57%14.08%14.03%13.30%16.59%
Revenue as Reported
10,94711,21211,3109,6259,1128,504
Advertising Expenses
-85.9635.82--45.64
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.